Article

Video: How to Follow an Adrenal Incidentaloma

To image or not to image: A new study validates professional society recommendations on follow-up strategies for adrenal masses. 

 

In 2016, the European Society of Endocrinology (ESE), in collaboration with the European Network for the Study of Adrenal Tumors, asserted that adrenal incidentalomas <4 cm and ≤10 Hounsfield units do not require follow-up imaging.

A paper recently published in the European Journal of Endocrinology reports results of a study designed specifically to assess the application of the recommended follow up strategies.

The retrospective cohort study looked at clinical characteristics and natural course of incidental adrenal masses in a single center over 13 years in more than 1000 patients.

The authors conclusions helped validate recommendations from the ESE that no follow up imaging is needed for adrenal masses less than 4 cm that have clearly benign features.

Source: Hong AR, Kim JH, Park KS, et al. Optimal follow-up strategies for adrenal incidentalomas: reappraisal of the 2016 ESE-ENSAT guidelines in real clinical practice. Eur J Endocrinol. 2017;177:475-483

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
© 2025 MJH Life Sciences

All rights reserved.